Albuminuria is an abnormal elevation of albumin in urine and is a common urinary marker associated with kidney injury and cardiovascular risk. It is typically assessed using the urine albumin-to-creatinine ratio (UACR).
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07405216 |
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease |
RECRUITING | PHASE4 |
| NCT07175051 |
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin |
RECRUITING | PHASE2 |
| NCT07173062 |
Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome |
RECRUITING | NA |
| NCT06954090 |
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT06621862 |
Clinical Findings and Albuminuria as Predictors of Acute Kidney Injury in Patients With Acute Heart Failure |
NOT_YET_RECRUITING | |
| NCT06374043 |
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. |
COMPLETED | PHASE4 |
| NCT06147232 |
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia |
NOT_YET_RECRUITING | PHASE2 |
| NCT06094920 |
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial |
COMPLETED | PHASE4 |
| NCT05881447 |
Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa |
RECRUITING | |
| NCT05838872 |
Evaluation of the Accuracy and Usability of the Minuteful - Kidney Urine Analysis Test System in the Lay User Hands |
COMPLETED | NA |
